The post Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance appeared on BitcoinEthereumNews.com. CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images) Getty Images Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all. Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features. Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for… The post Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance appeared on BitcoinEthereumNews.com. CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images) Getty Images Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all. Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features. Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for…

Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance

CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images)

Getty Images

Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all.

Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features.

Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for obvious reasons.

As the formerly inaccessible car, computer, and mobile phone make blindingly plain, the luxuries of the very rich foretell what we’ll all enjoy if markets are free. It’s that simple.

Which is the point of generic drugs. They’re brilliant pharmaceutical representations of what’s true in all walks of profit-motivated life. What’s expensive in the near-term, and as pharmaceutical companies recoup the enormous costs associated with funding their intrepid leaps, eventually is not.

All of which helps explain why 90 percent of pharmaceutical prescriptions filled are generic. It’s an essential progression.

Which is why pushback against Sens. Scott and Gillibrand is so necessary. For them to attack generic drugs, and in particular foreign-produced generics is for the senators to attack a progression that has long democratized access to life-enhancing and life-saving drugs. Worse, it’s an attack on the evolution of all market advances that are invariably an effect of globalized production.

At which point it’s quite simply odd that Scott would call into question the validity of the FDA’s inspections of foreign generics. The questioning implies an easy FDA that is belied by history, and that Republicans have long criticized as too stringent.

For now, healthcare and the drugs associated with it are frequently expensive. Which is the point. What’s great has to be initially expensive, but much more importantly, what’s inexpensive and accessible to all must initially be quite costly.

Thank goodness for the globalized production that eventually turns costly scarcity into abundance. Scott and Gillibrand should be thankful too, and retrieve legislation meant to suffocate the democratization of what improves life, and often saves it too.

Source: https://www.forbes.com/sites/johntamny/2025/10/28/generic-drugs-are-the-physical-manifestation-of-democratized-abundance/

Market Opportunity
Oasis Logo
Oasis Price(ROSE)
$0.01821
$0.01821$0.01821
+2.70%
USD
Oasis (ROSE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Pendle price eyes breakout above $2.35 resistance as new staking model goes live

Pendle price eyes breakout above $2.35 resistance as new staking model goes live

Pendle price is showing signs of recovery above a key resistance level as the protocol rolls out a new staking model. Pendle was trading at $2.07 at press time,
Share
Crypto.news2026/01/20 13:25
SEC clears framework for fast-tracked crypto ETF listings

SEC clears framework for fast-tracked crypto ETF listings

The post SEC clears framework for fast-tracked crypto ETF listings appeared on BitcoinEthereumNews.com. The Securities and Exchange Commission has approved new generic listing standards for spot crypto exchange-traded funds, clearing the way for faster approvals. Summary SEC has greenlighted new generic listing standards for spot crypto ETFs. Rule change eliminates lengthy case-by-case approvals, aligning crypto ETFs with commodity funds. Grayscale’s Digital Large Cap Fund and Bitcoin ETF options also gain approval. The U.S. SEC has approved new generic listing standards that will allow exchanges to fast-track spot crypto ETFs, marking a pivotal shift in U.S. digital asset regulation. According to a Sept. 17 press release, the SEC voted to approve rule changes from Nasdaq, NYSE Arca, and Cboe BZX, enabling them to list and trade commodity-based trust shares, including those holding spot digital assets, without submitting individual proposals for each product. A streamlined path for crypto ETFs Under the new rules, an ETF can be listed without SEC sign-off if its underlying asset trades on a market with surveillance-sharing agreements, has active CFTC-regulated futures contracts for at least six months, or already represents at least 40% of an existing listed ETF. This brings crypto ETFs in line with traditional commodity-based funds under Rule 6c-11, eliminating a process that could take up to 240 days. SEC chair Paul Atkins said the move was designed to “maximize investor choice and foster innovation” while ensuring the U.S. remains the leading market for digital assets. Jamie Selway, director of the division of trading and markets, called the framework “a rational, rules-based approach” that balances access with investor protection. First products already approved Alongside the new standards, the SEC cleared the listing of the Grayscale Digital Large Cap Fund, which tracks spot assets based on the CoinDesk 5 Index. It also approved trading of options tied to the Cboe Bitcoin U.S. ETF Index and its mini version, with…
Share
BitcoinEthereumNews2025/09/18 14:04
Masterpieces at Your Fingertips: Why Artplace is the Ultimate Revolution in Digital Art Galleries

Masterpieces at Your Fingertips: Why Artplace is the Ultimate Revolution in Digital Art Galleries

Art has long been perceived as an exclusive world—a realm reserved for the elite, tucked away in silent galleries and prestigious auction houses. However, the emergence
Share
Techbullion2026/01/20 13:33